GlassScriptPhysician profile
David P Huston
NPI 1164510996
$4,729.05
in general payments reported to CMS, 2019-2025
14 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,234 · 2020: $12.44 · 2023: $162 · 2024: $207 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $426 · Education: $57.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $426.02 |
| Education | $57.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $4,251.18 | 2019-2024 | Ruconest |
| Astrazeneca Pharmaceuticals LP | $105.83 | 2019-2025 | Fasenra, Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $66.16 | 2023-2024 | Takhzyro, Cuvitru |
| Glaxosmithkline, LLC. | $57.00 | 2023 | Arexvy |
| Fresenius Kabi USA, LLC | $52.50 | 2024-2025 | Stimufend, Tyenne |
| Csl Behring | $32.46 | 2024 | Haegarda |
| Novartis Pharmaceuticals Corporation | $28.80 | 2025 | |
| Blueprint Medicines Corporation | $27.51 | 2024 | Ayvakit |
| Biocryst US Sales Co., LLC | $22.76 | 2024 | Orladeyo |
| Grifols USA, LLC | $19.93 | 2023 | Xembify |
| Ars Pharmaceuticals Operations, INC. | $19.23 | 2025 | Neffy |
| Lilly USA, LLC | $19.19 | 2025 | Ebglyss |
| Curonix LLC | $14.06 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Genzyme Corporation | $12.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Huston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.